Ebvallo
As listed in the register: Ebvallo, Injektionsdispersion
·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tabelecleucelum
- Made by
- Pierre Fabre Pharma SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ebvallo wird angewendet als Monotherapie für die Behandlung erwachsener und pädiatrischer Patienten ab 2 Jahren mit rezidivierter oder refraktärer Epstein-Barr-Virus positiver Posttransplantations-lymphoproliferativer Erkrankung (EBV+ PTLD), die mindestens eine vorherige Behandlung erhalten haben. Bei Patienten mit solider Organtransplantation umfasst die vorherige Therapie eine Chemotherapie, es sei denn, eine Chemotherapie wird als ungeeignet erachtet.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pierre Fabre Pharma SA |
|---|---|
| Active substance | Tabelecleucelum |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01XL09 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Ebvallo, Injektionsdispersion |
| Packs | 1 bis 6 Durchstechflasche(n) |
| Zulassungsnummer | 69052 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.